Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410572 | 0.88 | QPCT (0.52) | QPCT | |
| SCHEMBL3818574 | 0.88 | QPCT (0.52) | QPCT | |
| SCHEMBL2382055 | 0.83 | QPCT (0.60) | QPCT | |
| SCHEMBL2381638 | 0.80 | QPCT (0.61) | QPCT | |
| SCHEMBL12274270 | 0.79 | QPCT (0.54) | QPCT | |
| SCHEMBL22753734 | 0.79 | QPCT (0.42) | QPCT | |
| SCHEMBL2383229 | 0.79 | QPCT (0.59) | QPCT | |
| SCHEMBL4299934 | 0.78 | QPCT (0.55) | QPCT | |
| SCHEMBL2381512 | 0.78 | QPCT (0.44) | QPCT | |
| SCHEMBL14148277 | 0.77 | QPCT (0.54) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545047-B9 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2015-06-10 | — | — | EP | claimed |
| EP-2545047-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2014-04-23 | — | — | EP | claimed |
| US-8269019-B2 | Inhibitors | PROBIODRUG AG (DE) | 2012-09-18 | — | — | US | claimed |
| EP-2545047-B9 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2545047-B9 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2545047-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2545047-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-8420828-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420828-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420828-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20120283259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120283259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120283259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2012-11-08 | — | — | US | disclosed |
| US-8269019-B2 | Inhibitors | PROBIODRUG AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269019-B2 | Inhibitors | PROBIODRUG AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269019-B2 | Inhibitors | PROBIODRUG AG (DE) | 2012-09-18 | — | — | US | disclosed |
| WO-2011110613-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224254-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224254-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224254-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224254-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885 |
| US-20120283259-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.